Liver injury leads FDA to pause Sanofi’s tests of MS drug acquired in $ 3.7B deal
Sanofi multiple sclerosis drug candidate tolebrutinib boasts a key feature: the ability to reach into brain and spinal cord tissue to provide its therapeutic effect. But liver problems have been reported in some patients dosed with the experimental treatment, leading the FDA to pause the drug’s pivotal clinical trials. According to Sanofi, the FDA based … Read more